These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 33634023)
1. Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma. Ge J; Li C; Xue F; Qi S; Gao Z; Yu C; Zhang J Front Oncol; 2020; 10():601175. PubMed ID: 33634023 [TBL] [Abstract][Full Text] [Related]
2. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy. Li YA; Zhao C; Ge JJ; Li C; Xue FJ; Qi SP; Zhao C; Kong CC; Zhang JP BMC Cancer; 2024 Jun; 24(1):754. PubMed ID: 38907215 [TBL] [Abstract][Full Text] [Related]
3. Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study. Wang Y; Meng X; Zhou S; Zhu Y; Xu J; Tao R Onco Targets Ther; 2019; 12():10579-10585. PubMed ID: 31819537 [TBL] [Abstract][Full Text] [Related]
4. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669 [TBL] [Abstract][Full Text] [Related]
5. Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option. Zhang HH; Du XJ; Deng ML; Zheng L; Yao DC; Wang ZQ; Yang QY; Wu SX Front Pharmacol; 2022; 13():969565. PubMed ID: 36060005 [No Abstract] [Full Text] [Related]
6. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review. Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma. Lin H; Zhou X; Sheng X; Liang X Drugs R D; 2023 Sep; 23(3):239-244. PubMed ID: 37466833 [TBL] [Abstract][Full Text] [Related]
8. Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature. Zhu Y; Zhao L; Xu Y; Zhan W; Sun X; Xu X Ann Palliat Med; 2022 Jan; 11(1):394-400. PubMed ID: 35144430 [TBL] [Abstract][Full Text] [Related]
9. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review. Wang Y; Xing D; Zhao M; Wang J; Yang Y PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828 [TBL] [Abstract][Full Text] [Related]
10. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study. Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812 [TBL] [Abstract][Full Text] [Related]
11. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
12. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016 [TBL] [Abstract][Full Text] [Related]
13. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas. Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis. Li G; Xu X; Cui J; Zhang F; Wang S Exp Ther Med; 2023 Sep; 26(3):452. PubMed ID: 37614429 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. Badruddoja MA; Pazzi M; Sanan A; Schroeder K; Kuzma K; Norton T; Scully T; Mahadevan D; Ahmadi MM Cancer Chemother Pharmacol; 2017 Oct; 80(4):715-721. PubMed ID: 28808777 [TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer. Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426 [TBL] [Abstract][Full Text] [Related]
17. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129 [TBL] [Abstract][Full Text] [Related]
18. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. Lu G; Rao M; Zhu P; Liang B; El-Nazer RT; Fonkem E; Bhattacharjee MB; Zhu JJ Front Neurol; 2019; 10():42. PubMed ID: 30766509 [TBL] [Abstract][Full Text] [Related]
19. Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study. Ge JJ; Li C; Qi SP; Xue FJ; Gao ZM; Yu CJ; Zhang JP BMC Cancer; 2020 Jan; 20(1):24. PubMed ID: 31914946 [TBL] [Abstract][Full Text] [Related]
20. The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study. Sun F; Lu S; Zhen Z; Zhu J; Wang J; Huang J; Zhang Y; Li H; Cai R; Liu M; Wu L; Sun X; Zhang Y Cancer Manag Res; 2020; 12():6177-6185. PubMed ID: 32801866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]